Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

Of course, not overnight. Ken has been at the helm for 2.5 months now and although the jury is still out on him we can summarize a little. He hasn’t delivered a winning blow to the shorts. He hasn’t done much if anything to convince buyers. As I said previously, I’d give him 1.5 more months before assigning him a final grade. So far, his legacy from Rosetta Genomics is what matters to the Wall Street in evaluating the future of Advaxis. Until proven otherwise, Ken is a continuation of Rosetta Genomics tenure. And it hurts us, the shareholders.